Table. 2.

Clinical characteristics of control and diabetic HRECs donors and CD34⁺ CACs subjects involved in the study.

HRECs donor #	Gender	Age	Diabetes duration	CVD	Retinopathy	Nephropathy	Neuropathy	Medications
Diabetic 1	Male	71	T2D 18 years	Yes	Moderate NPDR	Yes	No	Insulin
Diabetic 2	Male	66	T2D 16 years	Yes	Sever NPDR	Yes	No	Insulin Humalog and Humalin-N
Diabetic 3	Female	50	T2D 15 years	No	Sever NPDR	No	No	Insulin
Diabetic 4	Male	73	T2D 6 years	Yes	Mild NPDR	Yes	Yes	Insulin
Diabetic 5	Male	71	T2D 20 years	Yes	Moderate NPDR	Yes	No	Insulin
Diabetic 6	Male	62	T2D 22 years	Yes	Mild NPDR	Yes	No	Insulin
Diabetic 7	Male	70	T2D 15 years	Yes	Moderate NPDR	Yes	No	Insulin
Control 1	Female	58	No	No	No	No	No
Control 2	Male	56	No	Yes	No	No	No
Control 3	Male	71	No	No	No	No	No
Control 4	Female	52	No	No	No	No	No

CD34+ CACs subject #	Gender	Age	Diabetes duration	HbA1C	CVD	Retinopathy	Nephropathy	Neuropathy
Diabetic 1	Male	55	T2D 10 years	14	No	Sever NPDR	No	No
Diabetic 2	Female	58	T2D	6.5	No	Moderate NPDR	No	No
Diabetic 3	Female	59	T2D	7.1	No	Moderate NPDR	No	No
Diabetic 4	Male	41	T2D	14	No	PDR	No	No
Control 1	Female	57	No		No	No	No	No
Control 2	Male	49	No		No	No	No	No
Control 3	Female	39	No		No	No	No	No
Control 4	Female	58	No		No	No	No	No